Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 10/20 | 0.54 |
| ▸ | TGFBR1 | P36897 | 10/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2522580 | 0.86 | MAPK14 (0.62) | THRBTGFBR1MAPK14CSNK1DADORA2A | |
| SCHEMBL25230774 | 0.81 | CSNK1D (0.52) | THRBTGFBR1MAPK14CSNK1DADORA2A | |
| SCHEMBL2524801 | 0.80 | THRB (0.54) | THRBTGFBR1MAPK14CSNK1DADORA2A | |
| SCHEMBL25224798 | 0.76 | CSNK1E (0.46) | MAPK14CSNK1D | |
| SCHEMBL29994161 | 0.76 | THRB (0.58) | THRBTGFBR1MAPK14ADORA2AADORA2B | |
| SCHEMBL14845042 | 0.76 | THRB (0.58) | THRBTGFBR1MAPK14ADORA2AADORA2B | |
| SCHEMBL3110918 | 0.75 | THRB (0.54) | THRBTGFBR1MAPK14CSNK1D | |
| SCHEMBL17382369 | 0.74 | THRB (0.49) | THRBTGFBR1MAPK14CSNK1D | |
| SCHEMBL2522571 | 0.74 | THRB (0.49) | THRBTGFBR1MAPK14CSNK1D | |
| SCHEMBL17373680 | 0.74 | THRB (0.49) | THRBTGFBR1MAPK14CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | CSNK2A3, CSNK1A1, CSNK1G3 | THRB 2602/4885TGFBR1 3541/4885MAPK14 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.